John Aballi Net Worth

The estimated Net Worth of John Aballi is at least 182 千$ dollars as of 16 May 2024. John Aballi owns over 40,401 units of Exagen Inc stock worth over 122,415$ and over the last 2 years John sold XGN stock worth over 59,183$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

John Aballi XGN stock SEC Form 4 insiders trading

John has made over 3 trades of the Exagen Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently John bought 40,401 units of XGN stock worth 77,570$ on 16 May 2024.

The largest trade John's ever made was buying 90,000 units of Exagen Inc stock on 8 December 2022 worth over 241,200$. On average, John trades about 23,460 units every 75 days since 2022. As of 16 May 2024 John still owns at least 40,401 units of Exagen Inc stock.

You can see the complete history of John Aballi stock trades at the bottom of the page.

What's John Aballi's mailing address?

John's mailing address filed with the SEC is C/O EXAGEN INC., 1261 LIBERTY WAY, VISTA, CA, 92081.

Insiders trading at Exagen Inc

Over the last 5 years, insiders at Exagen Inc have traded over 8,628,989$ worth of Exagen Inc stock and bought 556,568 units worth 6,283,309$ . The most active insiders traders include James L L Tullis、Bio Exagen, L.P.H.I.G. Gpii...、Jeffrey Thomas Elliott. On average, Exagen Inc executives and independent directors trade stock every 48 days with the average trade being worth of 109,189$. The most recent stock trade was executed by John Aballi on 16 May 2024, trading 40,401 units of XGN stock currently worth 77,570$.

What does Exagen Inc do?

exagen diagnostics, inc. is a patient focused, discovery driven, clia-certified, cap-accredited laboratory with a growing menu of proprietary, internally developed tests focusing in the area of rheumatology and autoimmune diseases. committed to personalized medicine, our avise tests are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis and better disease management. for more information on our company, please visit www.exagen.com. for more information on avise testing services, please visit www.avisetest.com.

Complete history of John Aballi stock trades at Exagen Inc

Exagen Inc executives and stock owners

Exagen Inc executives and other stock owners filed with the SEC include:

• Fortunato Rocca,
  President, Chief Executive Officer and Director
• Fortunato Rocca,
  CEO, Pres & Director
• Kamal Adawi M.S., MBA,
  CFO & Corp. Sec.
• Dr. Debra Jeske Zack,
  Chief Medical Officer
• Kamal Adawi,
  Chief Financial Officer and Corporate Secretary
• Jeffrey Elliott,
  Independent Director
• Tina Nova,
  Independent Director
• Chet Burrell,
  Independent Director
• Brian Birk,
  Independent Chairman of the Board
• Bruce Robertson,
  Independent Director
• James Tullis,
  Independent Director
• Ebetuel Pallares,
  Independent Director
• Wendy Johnson,
  Independent Director
• Debra Zack,
  Chief Medical Officer
• Anja Kammesheidt,
  Chief Scientific Officer
• John Wegener,
  Sr. VP of Sales and Marketing
• Dr. Ming-Chou Lee Ph.D.,
  Chief Technology Officer
• Mark Hazeltine,
  Chief Operating Officer
• Frank Stokes,
  Director
• Scott D Kahn,
  Director
• Thierry Dervieux,
  Chief Scientific Officer
• James L Ltullis Growth Fund...,
  
• Bio Exagen, L.P.H.I.G. Gpii...,
  
• Dickerson Capital Focus Iii...,
  
• Holdings Limited Partnershi...,
  
• Co Investment Fund, L.P.Nms...,
  
• Paul Kim,
  Director
• Co Investment Fund, L.P.Sun...,
  
• Ana Hooker,
  Director
• John Aballi,
  President and CEO
• Mark Hazeltine,
  Chief Business Officer
• Jeffrey G. Black,
  Chief Financial Officer